Cite
HARVARD Citation
Pethusamy, K. et al. (2022). Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML. Leukemia & lymphoma. 63 (14), pp. 3426-3432. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Pethusamy, K. et al. (2022). Loss of TET2 with reduced genomic 5-hmC is associated with adverse-risk AML. Leukemia & lymphoma. 63 (14), pp. 3426-3432. [Online].